Andrew Berens
Stock Analyst at Leerink Partners
(1.87)
# 3,300
Out of 5,111 analysts
101
Total ratings
49.44%
Success rate
-3.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Upgrades: Outperform | $40 → $34 | $26.85 | +26.63% | 12 | Nov 20, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $104.97 | +41.95% | 3 | Nov 17, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $50 | $40.24 | +24.25% | 6 | Nov 10, 2025 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $5.78 | +159.52% | 1 | Oct 31, 2025 | |
| MRUS Merus | Downgrades: Market Perform | $95 → $97 | $96.82 | +0.19% | 6 | Oct 6, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $12.00 | +108.33% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $102.18 | -41.28% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $12.34 | -27.07% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $5.08 | +18.11% | 3 | Apr 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Market Perform | $880 → $762 | $752.62 | +1.25% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.20 | +931.25% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $25.97 | -3.74% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $119.78 | -19.85% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $98.64 | -20.92% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $19.01 | +47.29% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $91.56 | -13.72% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.40 | +1,828.57% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $10.82 | +131.05% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.33 | +531.91% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.43 | +2,657.20% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $16.45 | +21.58% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $9.12 | +174.12% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $14.17 | -43.54% | 7 | Jul 14, 2017 |
Agios Pharmaceuticals
Nov 20, 2025
Upgrades: Outperform
Price Target: $40 → $34
Current: $26.85
Upside: +26.63%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $104.97
Upside: +41.95%
Cogent Biosciences
Nov 10, 2025
Maintains: Outperform
Price Target: $18 → $50
Current: $40.24
Upside: +24.25%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $5.78
Upside: +159.52%
Merus
Oct 6, 2025
Downgrades: Market Perform
Price Target: $95 → $97
Current: $96.82
Upside: +0.19%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $12.00
Upside: +108.33%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $102.18
Upside: -41.28%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $12.34
Upside: -27.07%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $5.08
Upside: +18.11%
Regeneron Pharmaceuticals
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $752.62
Upside: +1.25%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $3.20
Upside: +931.25%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $25.97
Upside: -3.74%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $119.78
Upside: -19.85%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $98.64
Upside: -20.92%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $19.01
Upside: +47.29%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $91.56
Upside: -13.72%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.40
Upside: +1,828.57%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $10.82
Upside: +131.05%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.33
Upside: +531.91%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.43
Upside: +2,657.20%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $16.45
Upside: +21.58%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $9.12
Upside: +174.12%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $14.17
Upside: -43.54%